To the Editor,

We have read the article by Zhao ([@ref1]) entitled "Protective effects of trimetazidine and coenzyme Q10 on cisplatin-induced cardiotoxicity by alleviating oxidative stress and mitochondrial dysfunction" with great interest. The authors reported that trimetazidine and coenzyme Q10 showed protective effects against cispaltin-induced cardiotoxicity by reducing oxidative stress. First, we wish to ask the authors how they have rationalized the concentrations of trimetazidine (200 µM) and coenzyme Q10 (200 mg/L) they used in the ventricular myocytes? We would like to emphasize some important points about this well-written study.

Intracellular calcium plays a key role in cellular homeostasis. One of the most important mechanisms underlying chemotherapy-induced cardiotoxicity is increased calcium (Ca^2+^) levels in cardiomyocytes. Increased Ca^2+^ levels stimulate reactive oxygen species and there is a bidirectional interaction between these parameters ([@ref2]). It has been reported that trimetazidine shows cardioprotective effects by decreasing the intracellular calcium accumulation by controlling the membrane ion gradients ([@ref3]). It has been shown that caspase 3 and caspase 9 activites play an important role in mitochondrial apoptotic pathways ([@ref4]). Lui et al. ([@ref5]) showed that trimetazidine pretreatment could attenuate myocardial apoptosis and improve cardiac function by decreasing apoptotic rate and the expression levels of cleaved caspase 3 and 9.

Therefore, we think that measuring the aforementioned parameters, such as intracellular calcium levels and caspase 3 and caspase 9 activity, could provide insights into the cardioprotective role of trimetazidine in chemotherapy-induced cardiotoxicity.
